Ardelyx Loses Bid to Block HHS Classification of Kidney Drug

A federal judge dismissed biopharmaceutical company Ardelyx Inc.'s challenge of a US Department of Health and Human Services decision to identify its kidney disease treatment as a renal dialysis service.

Ardelyx, along with the American Association of Kidney Patients and the National Minority Quality Forum, lost its bid Friday to block the health agency’s classification of its kidney disease drug Xphozah as an “oral-only drug” that falls within the definition of “renal dialysis services,” according to opinion from Judge Beryl A. Howell of the US District Court for the District of Columbia dismissing the lawsuit.

Ardelyx had filed a lawsuit ...